Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
172 hedge funds and large institutions have $1.81B invested in Aerie Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 61 increasing their positions, 55 reducing their positions, and 23 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 3 → 9 (+6)
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
23% more capital invested
Capital invested by funds: $1.47B → $1.81B (+$343M)
11% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 55
8% more funds holding
Funds holding: 159 → 172 (+13)
20% less call options, than puts
Call options by funds: $8.78M | Put options by funds: $10.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$62.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.7M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$21.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.7M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$58.2M |
| 2 |
SIG
Senator Investment Group
New York
|
-$36.3M |
| 3 |
Millennium Management
New York
|
-$28.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$15.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.7M |
AERI Hedge Fund Activity: Q2 2017 in Review
172 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2017, worth a combined $1.81B — up 23% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AERI positions and 23 closed out — a net gain of 13 holders — while 61 added to existing stakes and 55 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $62.9M. The largest seller was Jennison Associates, cutting an estimated $58.2M.
- 172 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2017, up from 159 in Q1 2017.
- Funds reported $1.81B of Aerie Pharmaceuticals stock for Q2 2017, up 23% quarter-over-quarter.
- 36 funds opened new Aerie Pharmaceuticals positions in Q2 2017 and 23 closed out, a net change of +13 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2017 was Adage Capital Partners, an estimated $62.9M added.
- The largest Aerie Pharmaceuticals seller in Q2 2017 was Jennison Associates, an estimated $58.2M sold.
Based on aggregated 13F filings for Q2 2017.